News and Announcements
Market Advantage of Australia’s First Crypto Fund
- Published November 30, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Rise of cryptocurrency and blockchain in Australia has seen the popularity of fund managers and VCs targeting digital currencies.
- Australia’s First Crypto Fund are a first-mover in Australia.
- Global cryptocurrency and blockchain funds have intentions to expand to Australia given the increasing attention it is receiving here.
The rise of cryptocurrency and blockchain in Australia has seen fund managers and VCs switch their attention from traditional equity to these alternate forms of currencies.
Australia’s First Crypto Fund, founded by Dominet Venture Partners’ Domenic Carosa and Holger Arians and Wall Street veteran Henrik Andersson, is striving to attain a minimum of $30 million in digital currencies, ICOs and blockchain-based assets.
Australia’s First Crypto Fund is a first-mover in Australia giving them a great advantage. As the Australian crypto market gains traction, global blockchain funds, such as NEM.io, intend to expand their market to Australia. Mr Carosa of Australia’s First Crypto Fund said that “as the market continued to mature, he expected to see more funds targeting cryptocurrency and blockchain investments…for us, this is part of the market maturing and bringing more credibility to the space.
Australia’s First Crypto Fund will be worth $30 million with a minimum buy-in of $50,000. With success in their sights, the company will allocate some funds to Initial Coin Offerings (ICOs). Blockchain is one of the most compelling technological advancements in today’s society and will assist significantly in reshaping certain industries.
About Australia’s First Crypto Fund
Australia’s First Crypto Fund will invest in a mixture of digital assets, including major cryptocurrencies like Bitcoin and Ethereum, and as well as Initial Coin Offerings (ICOs) and high growth opportunities.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
